Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Sankyo licenses anticancer drug to Cyclacel

Executive Summary

Sankyo has licensed Cyclacel Ltd. (oncology therapeutics) worldwide rights, excluding Japan, to its small-molecule anticancer candidate CYC682 (sapacitabine).
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Reverse Licensing
    • Includes Contract
    • Marketing-Licensing

Related Companies

Advertisement
UsernamePublicRestriction

Register